Clinical Implications and Prognostic Values of Prostate Cancer Susceptibility Candidate Methylation in Primary Nonmuscle Invasive Bladder Cancer

Table 1

Baseline characteristics of subjects.

Variables	NC ()	NMIBC ()
Age, yrs (mean)	59.0 ± 22.2	64 ± 13.4
Gender, number of patients (%)
Male	6 (75.0)	107 (83.6)
Female	2 (25.0)	21 (16.4)
Number of tumors (%)
Single	—	76 (59.4)
Multiple	—	52 (40.6)
Tumor size (%)
<3 cm	—	76 (59.4)
≥3 cm	—	52 (40.6)
Grade, number of patients (%)
G1	—	38 (29.7)
G2	—	72 (56.2)
G3	—	18 (14.1)
T Stage
Ta	—	47 (36.7)
T1	—	81 (63.3)
Intravesical treatment, number of patients (%)
No	—	58 (45.3)
Yes	—	70 (54.7)
Recurrence-free survival, months (median)		44.5 (6.2–160.7)
Recurrence, number of patients (%)
No	—	90 (70.3)
Yes	—	38 (29.7)
Progression-free survival, months (median)		51.0 (6.6–160.7)
Progression, number of patients (%)
No	—	113 (88.3)
Yes	—	15 (11.7)

NC: normal control; NMIBC: nonmuscle invasive bladder cancer.